These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 19046817)

  • 1. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
    Pentheroudakis G; Greco FA; Pavlidis N
    Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
    Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
    Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    Kodaira M; Yonemori K; Shimoi T; Yoshida A; Yoshida M; Kitano A; Shimomura A; Yunokawa M; Shimizu C; Takiguchi Y; Fujiwara Y; Tamura K
    BMC Cancer; 2018 Feb; 18(1):176. PubMed ID: 29433539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching benchmarks in cancer of unknown primary: from autopsy to microarray.
    Pentheroudakis G; Golfinopoulos V; Pavlidis N
    Eur J Cancer; 2007 Sep; 43(14):2026-36. PubMed ID: 17698346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
    Pavlidis N
    Ann Oncol; 2012 Sep; 23 Suppl 10():x282-5. PubMed ID: 22987978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.
    Riihimäki M; Thomsen H; Hemminki A; Sundquist K; Hemminki K
    BMC Cancer; 2013 Jan; 13():36. PubMed ID: 23356713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
    Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
    Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic overview of chemotherapy effects in breast cancer.
    Bergh J; Jönsson PE; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
    JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
    Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
    J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
    Rassy E; Pavlidis N
    Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of various techniques/platforms with critical evaluation of each.
    Agwa E; Ma PC
    Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site.
    Møller AK; Pedersen KD; Abildgaard J; Petersen BL; Daugaard G
    Acta Oncol; 2010 May; 49(4):431-5. PubMed ID: 20235750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan.
    Yakushiji S; Ando M; Yonemori K; Kohno T; Shimizu C; Katsumata N; Fujiwara Y
    Int J Clin Oncol; 2006 Dec; 11(6):421-5. PubMed ID: 17180509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p16 expression in carcinoma of unknown primary: diagnostic indicator and prognostic marker.
    Vent J; Haidle B; Wedemeyer I; Huebbers C; Siefer O; Semrau R; Preuss SF; Klussmann J
    Head Neck; 2013 Nov; 35(11):1521-6. PubMed ID: 23345170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.
    Lazaridis G; Pentheroudakis G; Fountzilas G; Pavlidis N
    Cancer Treat Rev; 2008 Dec; 34(8):693-700. PubMed ID: 18584969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and therapeutic management of cancer of an unknown primary.
    Pavlidis N; Briasoulis E; Hainsworth J; Greco FA
    Eur J Cancer; 2003 Sep; 39(14):1990-2005. PubMed ID: 12957453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
    Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
    Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immune profiling for cancer of unknown primary site.
    Haratani K; Hayashi H; Takahama T; Nakamura Y; Tomida S; Yoshida T; Chiba Y; Sawada T; Sakai K; Fujita Y; Togashi Y; Tanizaki J; Kawakami H; Ito A; Nishio K; Nakagawa K
    J Immunother Cancer; 2019 Sep; 7(1):251. PubMed ID: 31519206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.